Why Is SELLAS LIFE SCIENCES (SLS) Stock Moving Today?

SLS stock is moving higher today after Goldman Sachs increased its stake in the biopharmaceutical company by 5.2% to 585,035 shares, valued at $8.64 million. The move comes as the stock has risen 6.4% over the last eight sessions, climbing from $11.86 to $12.61. With a market cap of $2.3 billion and a beta of 2.49, the stock is reacting to the institutional buildup amid ongoing challenges in its earnings performance and recent legal setbacks.

What Happened

Goldman Sachs has built a $75 million bet across multiple biotech stocks including SLS, signaling confidence in the sector ahead of potential catalysts. The firm’s increased position in SLS represents a significant vote of confidence from a major institutional investor. This follows a recent arbitration ruling that dismissed Sellas’ claims against 3D Medicines and ordered the company to pay about $1 million in legal fees. Sellas also reported second-quarter earnings that missed estimates, posting a loss of $0.05 per share compared to the expected $0.04 loss. Despite these headwinds, the Goldman Sachs investment appears to be driving renewed interest in the stock.

What The Data Shows

SLS has traded within a 52-week range of $1.39 to $15.88, and its recent price action shows a modest but consistent upward trend. The stock is currently trading at $12.61, up 6.4% over the past eight sessions. While the company remains unprofitable with a trailing twelve-month earnings per share of -0.23, the increased institutional ownership and biotech sector momentum may be influencing the stock’s direction.

What To Watch

Investors should monitor the company’s next earnings report and any developments related to its arbitration cases or partnership agreements. Coverage breadth and institutional activity will also be key indicators of the stock’s near-term trajectory.